AgomAb Therapeutics NV (NASDAQ:AGMB) Short Interest Update

AgomAb Therapeutics NV (NASDAQ:AGMB) saw a large increase in short interest in the month of April. As of April 30th, there was short interest totaling 755,022 shares, an increase of 74.3% from the April 15th total of 433,265 shares. Based on an average daily volume of 172,021 shares, the days-to-cover ratio is presently 4.4 days. Currently, 2.1% of the company’s shares are sold short.

AgomAb Therapeutics Stock Performance

NASDAQ:AGMB opened at $10.51 on Wednesday. The firm has a 50-day moving average of $11.61. AgomAb Therapeutics has a 12 month low of $9.00 and a 12 month high of $17.45.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Zacks Research raised AgomAb Therapeutics to a “hold” rating in a research report on Wednesday, March 4th. Morgan Stanley began coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They issued an “overweight” rating and a $28.00 target price on the stock. Leerink Partners began coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $36.00 target price on the stock. JPMorgan Chase & Co. began coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They issued an “overweight” rating and a $32.00 target price on the stock. Finally, Wall Street Zen raised AgomAb Therapeutics to a “hold” rating in a research report on Tuesday, February 17th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, AgomAb Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.